Celemics셀레믹스

Celemics remains loss-making with shrinking revenue, though its share price has risen sharply over the past year and fell in the last month.

Celemics is a Korean genetic analysis company selling sequencing kits, testing services and related analysis tools to hospitals, labs, pharma firms and research institutes. On a trailing basis to H1 2026 it booked about ₩5.2B of revenue against an operating loss of about ₩3.9B and a net loss of about ₩10.2B, and it carries ₩16.2B of borrowings against ₩37.1B of cash. The shares closed at ₩9,670 on 2026-10-23, roughly 223% above a year earlier but down 14.8% over one month and well below the 52-week high of ₩19,840.

What stands out

• Revenue fell 14.2% in 2025 to about ₩5.8B, after a 2024 year that was only slightly up, and operating margin remained deeply negative at -57.6%.
• The 2024 net income of about ₩12.3B is out of line with its operating loss, so it should not be read as a sign of underlying profitability.
• Trailing free cash flow is about -₩3.6B and liabilities are 60.5% of equity, so the business depends on its cash balance and funding.
• The filings list a rights offering (paid-in capital increase) decision that was amended in September 2026, along with stock purchase option grants and several insider and 5%+ holding reports.
• Valuation shows a P/B of 3.6 and a P/S of 20.7 with no P/E because earnings are negative; the in-data DCF base value is ₩858, far below the share price, and the bear and bull figures are listed as ₩1,079 and ₩546 respectively.

What to watch

• Details and timing of the rights offering, since new share issuance can dilute existing holders.
• The next periodic filings and whether revenue stabilises while operating losses narrow.
• Foreign ownership fell from 1.3% to 1.1% over 60 days, and the data contains no recent news headlines to explain the price moves.